CVS Health announced updates to its commercial drug formularies, reintroducing Zepbound (tirzepatide) and removing coverage blocks on Foundayo, expanding affordable GLP-1 weight management medication options for members. These changes aim to increase access and reduce costs through negotiations with drug manufacturers, addressing the high prices that have limited patient access. CVS Caremark expects these updates to drive savings for plan sponsors while offering more choices to patients. The company will support customers and members with communication and educational resources to ensure smooth transitions to covered therapies.
Aetna, part of CVS Health, has introduced the second generation of its AI-driven Claims Assist Manager (CAM) to enhance the efficiency and accuracy of insurance claims processing. This platform uses AI to reduce processing time by over 20% for comple...
This week, investors focus on key inflation data with Thursday's core PCE price index report, the Fed's preferred inflation gauge, expected at 3.3%, influencing rate decisions under new Fed Chair Kevin Warsh. A series of Federal Reserve speeches will...
